HDx therapy

Treatment effects and therapy implications with the THERANOVA dialyzer

In two clinical studies, comparing the THERANOVA dialyzer with the latest generation high-flux dialyzer, the THERANOVA dialyzer demonstrated enhanced purification across a wide range of large middle molecules.1,2

Overall clearance

Reduction ratio

Cordiax is a trademark of Fresenius Medical Care Deutschland GmbH.

Read the full report

PerCom Trials

Click the following link to read the full PerCom trial report published in the NDT Journal

The Nephrology Dialysis Transplantation (NDT) Journal gives you the opportunity to take a closer look at the PerCom study results and discover the clinical benefits of an HDx therapy option for your chronic HD patients.

  • Two clinical studies comparing the THERANOVA dialyzer with latest generation high-flux dialyzers
  • Enhanced blood purification of wide range of large middle molecule.
  • Greater clearances and intradialytic reduction ratios than regular HD - at ordinary blood flow rates
  • Similar to greater removal in comparison to high-volume HDF
  • Albumin removal limited to between 1 and 4 grams
Take me to the PerCom study
Additional resources

Want to read more about HDx therapy achieved through membrane innovation? Download the resources below to get more information.

ARTICLE

C. RONCO ET AL.

ARTICLE, 2017

Expanded Hemodialysis Innovative Clinical Approach in Dialysis

This book contains emerging evidence and fascinating new hypotheses on HDx. It is highly recommended for all physicians and healthcare professionals who are caring for dialysis patients and are seeking innovation and improved care solutions. The material is available on-line for free by downloading the individual chapters (available in PDF format).

Reference: DOI: 10.1159/000479262

Article
READ MORE

ARTICLE

M. BELMOUAZ ET AL.

ARTICLE, 2017

Comparison of hemodialysis with medium cut-off dialyzer and on-line hemodiafiltration on the removal of small and middle-sized molecules.

This study shows that the use of MCO (Theranova) dialyzer in HD produces similar removal of urea, creatinine, β2-microglobulin and myoglobin as does ol-HDF, with good tolerance profile and without modification of nutritional status

Reference: Clin Nephrol. 2017 Aug 30. doi: 10.5414/CN109133.

ARTICLE
READ MORE

ARTICLE

Ronco C.

ARTICLE, 2017

The Rise of Expanded Hemodialysis

This article is describing the rise of a new concept therapy called "expanded hemodialysis" - "This new therapy is likely to modify the outcome of endstage kidney disease patients, thanks to the enhanced removal of molecules traditionally retained by current dialysis techniques."

Reference: Blood Purif 2017;44:I-VIII

Article
READ MORE

ARTICLE

C. ZWEIGART, A. BOSCHETTI-DE-FIERRO, M. HULKO, et al

ARTICLE, 2017

Medium cut-off membranes - closer to the natural kidney removal function

A comprehensive editorial on novel MCO membranes for expanded hemodialysis to remove large middle molecules that are less effectively removed with conventional membranes

Reference: DOI:10.5301/ijao.5000603

Article
READ MORE

ABSTRACT #SA-PO760

J. BAHARANI ET AL

ABSTRACT #SA-PO760, ASN 2017

Clinical Experiences of a New Expanded Hemodialysis Therapy with a Novel Medium Cut-Off Dialyzer

HDx therapy was convenient, simple to implement, and achieved high β2M RRs with low albumin loss. It offers opportunity for achieving the clearance of middle molecules delivered by HDF, when patient factors exist or HDF is not available. Based on 2 of 4 HDF patients and all 14 HDx patients.

Abstract .PDF/139 KB
DOWNLOAD

ABSTRACT #P33

M. HULKO ET AL

Abstract #P33, ESAO 2017

Sieving coefficients of hemodialysis membranes

This study shows that care must be taken when SC of dialyzers are compared when the intended use is only partly the same but not identical. This study thus offers SC obtained under identical conditions.

Abstract
READ MORE

ABSTRACT#SP488

M. HULKO ET AL

Abstract #SP488, ERA-EDTA 2017

Retention of different types of pyrogens by membranes of different pore size

In this study dialyzer membranes of different pore sizes were tested for their capacity to prevent pyrogens crossing from dialysate to blood side and differentiating between PG, LPS, and bDNA.

Abstract
READ MORE

ABSTRACT #SA-PO761

S.KOBALL ET AL.

ABSTRACT #SA-PO761, ASN 2017

Comparison of Albumin Binding Capacity and Uremic Toxins in Hemodiafiltration versus Novel Dialysis Membrane

Expanded hemodialysis enabled by Theranova demonstrates equal effects on ABIC and uremic toxins in comparison to OL-HDF.

Abstract .PDF/134 KB
DOWNLOAD

ABSTRACT#MP537

E. SCHEPERS ET AL

Abstract #MP537, ERA-EDTA 2017

Does increasing membrane pore size affect endotoxin permeability? A novel dialysis simulation set-up

In the present study a realistic dialysis set-up was developed and therewith permeability for bacterial degradation products of 4 commercial dialyzers of comparable composition but with increasing pore size was tested.

Abstract
READ MORE

ABSTRACT#MP527

U. TEATINI ET AL

Abstract #MP527, ERA-EDTA 2017

Removal evaluation of a new dialyzer with medium cut-off membrane in HD treatments

This study was addressed to evaluate the removal efficacy of Theranova® in standard HD by the Reduction Rate (RR) in comparison with our data achieved with three different types of online postdilution HDF treatments

Abstract
READ MORE

ABSTRACT#MP538

U. TEATINI ET AL

Abstract #MP538,ERA-EDTA 2017

A short-term report of HD treatments with the new Theranova dialyzers

In this study the removal efficacy of THERANOVA in standard HD in a case study was evaluated.

Abstract
READ MORE

Report

Baxter. Data on file.

Report, 2016

THERANOVA limited Controlled Distribution Report

Selected dialysis centres were chosen post-approval to share their first experiences using THERANOVA in clinical settings.

REPORT .PDF / 425 KB
Download

POSTER #FP478

A. Boschetti De Dierro, M. Voigt, M. Storr, B. Krause

POSTER # FP478, ERA-EDTA 2015

MCO (Medium Cut-Off Membranes: Enhanced Selectivity in High-Flux Class)

A comprehensive in vitro characterization of THERANOVA dialyzer's novel MCO high-flux membrane for hemodialysis, showing permeability close to that of the natural kidney.4

Poster .PDF / 225 KB
Download
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au
www.baxterprofessional.co.nz

Poster#SAT-481

A. Boschetti de Fierro, M. Voigt, M. Hulko, M. Storr, B. Krause

Poster #SAT-481, WCN 2015

MCO Dialyzers:
Enhanced Selectivity High-Flux

Using in vitro data, a study assess the effectiveness of MCO dialyzers in simulated hemodialysis (HD) and hemodiafiltration (HDF) treatments.5

Poster .PDF / 74 KB
Download
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au
www.baxterprofessional.co.nz

Poster#FP504

M. HULKO, M. EBBERS, M. YILDIRIM, S. HOMEYER, B. KRAUSE

Poster #FP504, , ERA-EDTA 2015

Hemoglobin removal by dialyzers of different permeability profiles

A study measuring cell-free plasma hemoglobin clearance of conventional high-flux dialysis filters, high-flux filters with extended permeability and high cut-off dialyzers.6

Poster .PDF / 98 KB
Download
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au
www.baxterprofessional.co.nz

Poster#FP516

M. HULKO, A. GEKELER, I. KOCH, V. DIETRICH, B. KRAUSE

Poster #FP516, ERA-EDTA 2015

Dialysis membrane pore size does not determine LPS retention

A study to challenge the belief that dialysis membranes having larger pore sizes are less effective in retaining LPS in dialysis fluid than low-flux, high-flux and high flux membrane of the same material and structure.7

Poster .PDF / 90 KB
Download
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au
www.baxterprofessional.co.nz

POSTER #SP426

M. HULKO, A. GEKELER, I. KOCH, V. DIETRICH, B. KRAUSE

Poster #SP426, ERA-EDTA 2015

Changes in coagulation factors and inhibitors during simulated HD with the novel medium cut-off high flux membrane

An investigation across a set of coagulation factors and inhibitors (molecular weight 50 to 71.6 kDa) during in-vitro dialysis with highly permeable dialysis membranes.8

Poster .PDF / 242 KB
Download
close

Available now - you are invited to view a presentation showcasing the latest advances in hemodialysis membrane technology: patient centred care

Filmed at a recent Symposium at Perth, proudly sponsored by Baxter Healthcare, Professor Colin Hutchison and Dr Markus Storr explore:

  • Middle molecules and the impact to the patient
  • The advances of mid cut off membrane technology designed for the removal of middle molecules
  • The relevance to dialysis today

PROFESSOR

COLIN HUTCHINSON

Hawkes Bay District
Health Board, New Zealand Professor Colin Hutchison is the Director of Nephrology and Head of Medicine at Hawke’s Bay District Health Board Hastings, New Zealand. Professor Colin Hutchison talks about the latest research in middle molecule evidence, and our current capacity to clear with dialysis.

DR MARKUS STORR

Baxter Healthcare
Hechingen, Germany
Markus Storr is a senior manager at Baxter’s Research and Development Department in Hechingen, Germany. Dr Markus Storr, outlines the methods of middle molecule removal, current and future innovations with enhanced selectivity.

Presentation available now - log in or sign up to www.baxterprofessional.com.au
www.baxterprofessional.co.nz

Stay updated on our latest clinical findings

Sign-up today and ensure that you are always aware of the most recent news and clinical results including:

  • Our latest scientific findings
  • New journal publications
  • Ongoing trials and results
  • And more on our global research partnerships.